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Isoxsuprine hydrochloride is a peripheral vasodilator. It is advisable to prepare the drug in sustained release dosage forms to improve patient compliance and to achieve a steady state blood level with minimum side effects. Different hydrophilic and hydrophobic polymers in addition to their combinations were used in different ratios to select the best level of the matrix forming material that provides the most sustaining effect. The effect of different types and concentrations of polymers on the release rate of the drug was investigated. The drug release decreased by increasing the concentration of the polymer in all the studied formulations. Tablet formula containing either 30% (w/w) HPMC 15000 or 30% (w/w) Eudragit RSPM gave the most sustaining effect among the single polymers. The drug release rate from tablets prepared using polymer blends is slower compared to that from those containing single polymers. The slowest drug release was obtained from tablet formulae containing: drug, 10% (w/w) HPMC 15000 and 40% (w/w) Eudragit RSPM and drug, 10% (w/w) Eudragit RSPM and 40% (w/w)
Eudragit RLPO. The release of isoxsuprine HCl from matrices prepared using single polymer followed Higuchi's diffusion model. However, zero-order release kinetics was elucidated for the
INTRODUCTION
Pharmaceutical methods for extending drug action involve the design of the dosage form in such a way that it affects the release rate of the drug without affecting its chemical or biological characteristics. Among the methods used to formulate oral extended release products is retardation of drug release by the use of polymeric materials 1 . Polymers are uniquely suited as materials of construction for oral delivery systems. The polymers offer a wide range of properties such as diffusivity, permeability, and solubility that are important to achieve controlled delivery. These polymers have been broadly grouped into water-soluble polymers (hydrophilic polymers) and waterinsoluble polymers (hydrophobic polymers) 2 . The increasing need for suitable polymers to achieve a desired drug release has facilitated screening of a large variety of both synthetic and natural polymers for their ability to retard the release of specific drug substances. Since the cost of synthesizing a new polymeric substance and testing for its safety is costly and tedious, a new focus has been directed towards investigating the use of polymer blends of pharmaceutically approved polymeric materials as matrix excipients to retard drug release 3 . However, these systems are more complex than coatings based on only one polymer and care has to be taken when using this type of formulations. The use of polymer blends as coating materials for controlled drug delivery systems can offer major advantages, including: (i) facilitated adjustment of desired drug release patterns, mechanical properties and drug release mechanism 4 , (ii) improved film formation and storage stability 5 , and (iii) the possibility to develop novel strategies for site specific drug delivery within the gastrointestinal tract 6 . Hence, isoxsuprine HCl sustained release tablets were formulated using different hydrophilic polymers namely; methyl cellulose (MC), sodium carboxymethyl cellulose (NaCMC) and hydroxypropyl methyl cellulose 15000 (HPMC 15000) in addition to hydrophobic polymers; ethyl cellulose (EC) and methacrylate copolymers; Eudragits RS100, RL100, RLPO and RSPM either single or in combinations. The prepared tablet formulations were tested for their drug content uniformity, weight uniformity, tablet diameter, tablet thickness, friability and hardness. The release of the drug from the prepared tablets was also studied. The in-vitro release profiles of isoxsuprine HCl from the prepared tablets were constructed and analyzed to determine the release kinetics of the drug from the formulations. 
MATERIALS AND METHODS

Materials
Methods
Preparation of isoxsuprine HCl sustained release tablets
Isoxsuprine HCl sustained release tablets were prepared by mixing isoxsuprine HCl (20 mg/tablet) with the different studied polymers either single or in combinations in different weight ratios and the other additives. Single polymers were added in the following weight ratios, 3:1, 2:1, 3:2, 1:1, 1:2 and 1:3, drug : polymer and these polymer ratios represent the following percentage from the tablet weight 3.34%, 5.00%, 6.67%, 10.00%, 20.00% and 30.00% respectively. In case of polymer combinations, four weight ratios were used 1:1:1, 1:1:2, 1:1:3 and 1:1:4, drug : polymer 1 : polymer 2, respectively. Diluent was added and mixing was performed using the serial mixing procedure in a mortar for at least five minutes for each step. This was followed by tumbling mixing in a clean glass bottle for about fifteen minutes. Magnesium stearate was then added to the blend and mixed for another five minutes. The produced mixtures were compressed into tablets using single punch tablet machine equipped with a flat faced 8 mm punch. The machine was adjusted to produce tablets weighing 200 mg. Tables 1-4 , show the composition of the prepared isoxsuprine HCl sustained release tablet formulations and the amount of each ingredient in milligram (mg). Isoxsuprine HCl sustained release tablet formulations prepared using hydrophilic polymers are given the symbols (D1-D19). The prepared isoxsuprine HCl sustained release tablet formulations containing hydrophobic polymers are given the symbols (D20-D49). The symbols (D50-D69) are given to the tablets prepared using polymer blends.
The prepared isoxsuprine HCl sustained release tablets were evaluated for the following parameters 7 : tablet weight uniformity, drug content uniformity, tablet friability, tablet diameter, tablet thickness and tablet hardness.
In-vitro release of isoxsuprine HCl from the prepared sustained release tablets
The USP dissolution apparatus II (paddletype) rotating at 100 rpm was utilized. The dissolution medium was 500 ml of dilute HCl (pH 1.2) for the first 2 hrs, after which the pH of the dissolution medium was increased to pH 6.8 by adding tribasic sodium phosphate powder 8 . The dissolution medium was previously degassed and warmed to 37±0.5°C. At the specified time intervals, samples of 5 ml were withdrawn from the dissolution medium using volumetric pipette with cotton plug at its tip and replaced immediately with the same volume of the fresh dissolution medium maintained at the same temperature. The amount of isoxsuprine HCl was determined spectrophotometrically at λ max 275 nm, using the same dissolution medium as a blank. All assays were done in triplicates and the mean value and standard deviation (SD) were calculated. For all formulae: total tablet weight was 200 mg and magnesium stearate 1% of total tablet weight was used as a lubricant. For all formulae: total tablet weight was 200 mg and magnesium stearate 1% of total tablet weight was used as a lubricant. For all formulae: total tablet weight was 200 mg and magnesium stearate 1% of total tablet weight was used as a lubricant. -80  39  39  D62  --20  -20  69  69  D63  --40  -20  59  59  D64  --60  -20  49  49  D65  --80  -20  39  39  D66  ---20  20  69  69  D67  ---40  20  59  59  D68  ---60  20  49  49  D69  ---80  20  39  39 For all formulae: total tablet weight was 200 mg and magnesium stearate 1% of total tablet weight was used as a lubricant.
Kinetic analysis of the drug release from the prepared sustained release tablets
The kinetic parameters for the in-vitro release of isoxsuprine HCl from the prepared sustained release tablets were determined and analyzed in order to explain the mechanism of the drug release. The kinetic data were plotted by linear regression according to zero and firstorder kinetics as well as simplified Higuchi model.
RESULTS AND DISCUSSION
Standard calibration curves of isoxsuprine HCl in 0.1 N HCl solution of pH 1.2 and phosphate buffer of pH 6.8 were found to obey Lambert-Beer's law within the concentration range (2-20 µg/ml). Isoxsuprine HCl sustained release tablets prepared using different polymers were uniform in weight and tablet weights of all the studied formulations were found to be within the Pharmacopeial limits. Isoxsuprine HCl sustained release tablets were uniform in thickness and diameter. The values of friability (% loss) were ranged from 0.364 to 0.611%, which are acceptable values as the % loss must not be more than 1%. The hardness values of tablets were within the range of 4.5-7.1 kg which is also accepted range of hardness variation 9 .
In-vitro release of isoxsuprine HCl from the prepared sustained release tablets Figures 1-3 show the efect of different ratios of the investigated hydrophilic polymers on isoxsuprine HCl release from the prepared tablets using pH-shift method. Figure 1 shows the release profiles of isoxsuprine HCl from the prepared tablets containing different ratios of MC. The release of isoxsuprine HCl from tablets containing the drug alone (Formula D1) is rapid and complete drug release is obtained after 45 min. The incorporation of MC in isoxsuprine HCl tablets with different ratios (Formula D2-D7) resulted in a decrease in the release rate of isoxsuprine HCl from these tablets than that from tablets containing the drug alone (Formula D1). This sustaining in the drug release may be attributed to the presence of MC, which is a non-ionic swelling hydrophilic polymer. The process of release of the drug from the hydrophilic polymer-drug matrix involves water penetration into the dry matrix, hydration and gel formation of this polymer followed by the diffusion of the dissolved drug in the gel 9 . As shown in figure 1 , the release rate of isoxsuprine HCl was slowed upon increasing the concentration of MC from 3.34 to 30% (w/w). About 88% of the drug was released from the tablets containing 3.35% (w/w) MC, formula D2, after 90 min., while the tablets containing 30% (w/w) MC, formula D7 released about 69% of the drug after the same time. This decrease in the drug release rate may be due to the increase in the thickness of the gel layer upon increasing the concentration of the polymer in the tablets. Figure 2 shows the release profiles of isoxsuprine HCl from tablets prepared using different ratios of NaCMC. It is clear that the drug release rate decreased as the percent of NaCMC in the matrix is increased. The presence of 30% (w/w) NaCMC in the tablet (formula D13) sustained the release of isoxsuprine HCl to 5 hrs. This sustaining effect of the drug release can be attributed to the presence of NaCMC, which is swellable cellulose ether. Upon hydration, tablets containing NaCMC, behaved as a gel-like system, thereby creating a gelatinous barrier through which the drug diffuses during the dissolution process. The formation of such a gel layer around the drug particles might account for the retardation of the drug release from the prepared tablets 10 . Similar behaviour was observed with matrix tablets containing diltiazem HCl and NaCMC Figure 4 shows the release profiles of isoxsuprine HCl from tablets containing 30% (w/w) of different hydrophilic polymers. As shown from this figure, HPMC 15000 (formula D19) shows the most sustaining effect (complete drug release was obtained after 7 hrs) when used in the attributed to its nature as a highly swellable non-ionic hydrophilic polymer. The sustaining effect of the three tested hydrophilic polymers on drug release was found to be in the following descending order: HPMC 15000 > NaCMC > MC. In order to highlight the differences found in the release profiles of the three different formulae (D7, D13 and D19) in addition to formula D1 containing drug alone, t 50% and t 90% have been calculated and their values are reported in table 5. t 50% and t 90% are the time needed for the release of 50% and 90% of the total amount of drug contained in the tablet. Formula (D19), containing 30% (w/w) HPMC 15000, showed the highest values of t 50% and t 90% and this confirmed that isoxsuprine HCl tablets prepared using 30% (w/w) HPMC 15000 gave the most sustaining effect of isoxsuprine HCl release among the studied hydrophilic polymers. Generally, it could be observed that the release of isoxsuprine HCl from all the prepared formulations in acidic medium was pronouncedly more rapid than in phosphate buffer (pH 6.8). This initial rapid release of isoxsuprine HCl from the sustained release tablets in pH 1.2 may be attributed to the presence of the drug in higher concentration in the ionized form (salt form), which has higher solubility than the base, hence the drug particles close to the tablet surface might be released first giving this initial higher release of the drug 14 . Moreover, the viscosity of the gel layer around the drug may decrease in acidic medium. By increasing the pH of the dissolution medium, more sustaining drug release was obtained and this may be due to the increase in the viscosity of the gel layer 14 . Figures 5-9 show the effect of different ratios of the investigated hydrophobic polymers on isoxsuprine HCl release from the prepared tablets using pH-shift method 8 . Figure 5 shows the release profiles of isoxsuprine HCl from the prepared tablets containing different ratios of EC. The drug release decreased upon the incorporation of EC. This decrease may be attributed to the nature of EC, which is a hydrophobic cellulose ether that forms a thick coat around the drug particles. Upon contacting with the dissolution medium, diffusion and dissolution of the drug through water filled capillaries within the pore 15 . The release rate of isoxsuprine HCl decreased as the percent of EC increased from 3.34 to 30% (w/w). This increase in the sustaining of the drug release may be due to the increase in the thickness of the insoluble EC coat formed around the drug particles. The maximum sustaining, about 5 hrs, of the drug release was obtained from formula D25 containing 30% (w/w) EC. Figure 6 illustrates the release profiles of isoxsuprine HCl from tablets prepared using Eudragit RL100. It is clear from this figure that the drug release decreased as the percent of Eudragit RL100 increased and the maximum release duration (5 hrs) was obtained in case of formula D31, containing the drug and 30% (w/w) Eudragit RL100. This decrease in the drug release may be attributed to the nature of Eudragit RL100, which is an acrylic copolymer that forms water-insoluble coat with defined permeability to water and to dissolved drugs. Figure 7 shows the release profiles of isoxsuprine HCl from tablets containing different ratios of Eudragit RS100. As shown in this figure, drug release is markedly decreased due to the presence of Eudragit RS100 that forms a low permeable coat around the drug particles. This coat has a relatively strong sustaining effect on drug release and the maximum retardation was obtained in case of formula D37 which contains 30% (w/w) Eudragit RS100. The effect of different percentages of Eudragit RSPM on the release of isoxsuprine HCl from the prepared tablets is shown in figure 8 . It is clear that the drug release was markedly decreased when the percentage of Eudragit RSPM increased in the tablet formulation. The complete drug release was obtained after 8 hrs in case of formula D43 containing 30% (w/w) of this polymer. Figure 9 shows the release profiles of isoxsuprine HCl from tablets prepared using different ratios of Eudragit RLPO. The release of isoxsuprine HCl from these tablets decreased by increasing the polymer content in the tablet. Figure 10 shows the drug release profiles of isoxsuprine HCl from tablets containing 30% (w/w) of different hydrophobic polymers. It is clear that the sustaining effect of the investigated hydrophobic polymers on the drug release can be arranged in the following descending order: Eudragit RSPM > Eudragit RLPO > Eudragit RS100 > Eudragit RL100 > EC. The maximum retardation effect on the drug release was obtained in case of Eudragit RSPM and this may be attributed to its pHindependent solubility properties and the low permeability to water-soluble drugs 16 . Table 6 shows t 50% and t 90% values of isoxsuprine HCl release from tablets containing 30% (w/w) of different hydrophobic polymers. It is clear that tablet formula (D25) containing EC has the least t 50% and t 90% values among the studied hydrophobic polymers. Tablet formula (D43) containing Eudragit RSPM shows the highest t 50% and t 90% values and this confirmed that isoxsuprine HCl tablets prepared using 30% (w/w) Eudragit RSPM gave the most sustaining effect on the drug release among the studied hydrophobic polymers. Isoxsuprine HCl tablets containing 30% (w/w) Eudragit RS100 (formula D37) show more sustaining of drug release than those containing 30% (w/w) Eudragit RL100 (formula D32) and this may be attributed to that Eudragit RS100 has lower permeability to the aqueous solution and the active ingredient than Eudragit RL100. Generally, RS type of Eudragits has low permeability to aqueous solutions due to its lower content in quaternary ammonium functional groups which give rise to the permeability of the coat and the ammonium/meth-acrylic acid ester values are 1/40 and 1/20 for Eudragit RS-type and Eudragit RL-type, respectively 16 . The release profiles of isoxsuprine HCl from the prepared tablets containing different polymer blends are shown in figures 11-15.
The effect of different ratios of NaCMC on isoxsuprine HCl release from tablets containing 10% (w/w) HPMC 15000 is illustrated in figure 11 . It is clear that the isoxsuprine HCl matrix tablet prepared with a combination of Na CMC (ionic hydrophilic polymer) and HPMC 15000 (non ionic hydrophilic polymer) gave slower release of the drug than tablets prepared using 10% (w/w) HPMC 15000 alone, formula (D17). This may be due to the fact that, when the matrix tablet prepared using hydrophilic polymer comes into contact with water, it swells and forms a porous gel barrier, the pores near the surface of matrix are filled with water. The drug release is initially controlled by the dissolution of the drug in the water filled pores and then by diffusion
17&18
. The presence of NaCMC in the polymer blend resulted in the formation of a highly viscous solution in the pores up on dissolution, which in turn slowed down the drug release by the formation of an additional gel-like barrier. As shown in figure 11 , as the percentage of NaCMC increased in the polymer blend used for the preparation of isoxsuprine HCl matrix tablets, the synergistic retardation effect of the polymer blend increased and a valuable decrease of drug release rate can be achieved. Figure 12 shows the release profiles of isoxsuprine HCl from tablets containing 10% (w/w) HPMC 15000 and different ratios of EC. The drug release from tablets containing the polymer blend was less than that from tablets containing HPMC 15000 alone and this may be attributed to the presence of EC, which is a hydrophobic polymer, the admixture of HPMC with EC could change the permeability of the prepared matrix and consequently modify the release rate of the drug 19 . The maximum sustaining drug release was obtained from tablet formula: D57 that contains isoxsuprine HCl, 10% (w/w) HPMC 15000 and 40% (w/w) EC. Figure 13 illustrates the drug release profiles of isoxsuprine HCl from tablets containing 10% (w/w) HPMC 15000 and different percentages of Eudragit RSPM. It is clear from the figure that there was a marked decrease in the release of isoxsuprine HCl from the prepared sustained release tablets containing the blend of HPMC and Eudragit RSPM. Eudragit RSPM is a pH independent polymer with poor surface wettability and low swelling properties. Therefore, its combination with HPMC 15000 can result in a pronounced sustaining of drug release. As the percentage of Eudragit RSPM increased, the drug release decreased and the maximum drug release retardation was obtained when the blend of 10% (w/w) HPMC 15000 and 40% (w/w) Eudragit RSPM (formula D61) was used. The total drug release from this tablet formula was obtained after 12 hrs. The effect of different weight ratios of EC on the drug release from tablets containing 10% (w/w) Eudragit RSPM is shown in figure  14 . Results showed that the blend of EC and Eudragit RSPM at different percents reduced the drug release more than Eudragit RSPM alone (formula D41). It is clear from the figure that as the percentage of EC increased, the drug release from the prepared tablets decreased. The maximum time for total drug release (9 hrs) was obtained when 40% (w/w) EC was added to isoxsuprine HCl tablets containing 10% (w/w) Eudragit RSPM (formula D65). Figure 15 shows the drug release profiles of isoxsuprine HCl from tablets containing 10% (w/w) Eudragit RSPM and different ratios of Eudragit RLPO. It is clear that there was a marked decrease in the drug release from tablets containing different ratios of the polymer blend than the drug release from tablets containing 10% (w/w) Eudragit RSPM alone. This may be attributed to the synergistic retardation effect of the two hydrophobic polymers used.
As shown from figure 15 , as the ratio of Eudragit RLPO increased from 10% (w/w) to 40% (w/w), the sustaining effect on the drug release increased. Tablets containing 10% (w/w) Eudragit RSPM and 40% (w/w) Eudragit RLPO (formula D69) gave the least drug release and the total drug release was achieved after 12 hrs. Table 7 shows t 50% and t 90% values of isoxsuprine HCl release from tablets containing different polymer blends. It is clear that isoxsuprine HCl sustained release tablets containing single polymers (formulae D17 and D41) have the least values of t 50% and t 90% . Isoxsuprine HCl sustained release tablets containing the blend of 10% (w/w) HPMC 15000 and 40% (w/w) Eudragit RSPM (formula D61) as well as those containing the polymer blend of 10% (w/w) Eudragit RSPM and 40% (w/w) Eudragit RLPO (formula D69) have the highest value of t 50% and t 90% among the studied formulae. From the results obtained it is clear that these two types of polymer blends are preferable for the design of the oral sustained release product of isoxsuprine HCl, where the rate of the drug release was remarkably prolonged. 
